Biotechs Choosing Brazil For Drug Development And Early Sales
LATAM Provides A Significant Patient Population For Many Rare Conditions
Executive Summary
Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.
You may also be interested in...
Brazilian Industry Pushes For Clinical Research Bill To Proceed
Numerous organizations relating to the Brazilian pharmaceutical industry say that Brazil could become a research hotspot if it had better regulations.
PTC Eyes Transition From Capital-Raising To Money-Making Company
With $1.1bn in cash plus revenue from its existing commercial products and royalties from Roche’s sales of newly approved Evrysdi to invest in R&D, PTC Therapeutics may achieve profitability in 2023.
Brazil’s Spiraling Access Suits And The Potential Impact On Companies
Spending on medicines as a result of litigation against health authorities is soaring in Brazil. Scrip investigates the challenges firms may face in future, including greater pricing pressure, a more NICE-like health technology appraisal system and increased scrutiny over any perceived industry wrongdoing.